Vertiflex Superion Spacer Panel Reset To Give FDA More Review Time
This article was originally published in The Gray Sheet
Executive Summary
FDA's Orthopaedics and Rehabilitation Devices Panel had planned to consider Vertiflex's PMA for its Superion interspinous spacer device on Dec. 12, but the agency postponed the meeting to Feb. 20 give it more time to review device information.
You may also be interested in...
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier
To get regular approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.